- Published on
Surgery - Lung Cancer
Introduction
lung primary malignant tumor. The WHO classifies bronchocarcinoma as: Adenocarcinoma, large-cell carcinoma, squamous cell carcinoma, and adenosquamous carcinoma are classified as small cell (20%) and non-small cell (80%).
Etiology
Lung tumors in their primary form: It is believed that factors including asbestos exposure and smoking, whether active or passive, eventually produce in genetic alterations that promote neoplastic transformation.
Tumors typically originate in the main or lobar bronchi (refer to Fig. 2), whereas adenocarcinomas typically manifest in distant locations.
supplementary tumors One common location for metastases is the lung.
Risk Factors
Cigarette smoking, air pollution, occupational exposures (polycyclic hydrocarbons, asbestos, nickel, chromium, cadmium, radon).
Epidemiology
The most prevalent deadly cancer in the West (18% of all cancer fatalities globally), accounting for 35,000 annual deaths in the UK, and three times more common in men than in women.
H HISTORY
5% of cases may show no symptoms despite radiological abnormalities.
Primary cause: Chest discomfort, cough, hemoptysis, and recurrent pneumonia.
Owing to local invasion: For instance, palpitations (arrhythmias), hoarseness and a cow cough caused by the left recurrent laryngeal nerve, dysphagia in the oesophagus, and brachial plexus (Pancoast's tumor).
Weight loss, exhaustion, bone pain or fractures, fits—all may be signs of metastatic disease or paraneoplastic events.
History and Examination
It's possible that none exist.
monophonic wheeze that is fixed.
indications of a pleural effusion or lobar collapse.
symptoms of metastases, such as hepatomegaly or supraclavicular lymphadenopathy.
Horner syndrome.
Investigations
Diagnosis options include sputum cytology, CT or ultrasound-guided percutaneous biopsy, lymph node biopsy, bronchoscopy with brushings or biopsy, and CXR.
TNM staging: Using CT or MRI scans of the head, abdomen, and chest, as well as bone and PET scans, is based on tumor size, nodal involvement, and metastatic metastasis. It is possible to employ invasive techniques like video-assisted thoracoscopy or mediastinoscopy.
Blood: FBC, U&Es, Ca2+ ("bone metastases"), AlkPhos, and LFT. Hypercalcemia is a prevalent condition.
Pre-operative care includes an assessment of general anesthesia, V/Q scan, ECG, and echocardiography, as well as pulmonary function testing (FEV1 >80% anticipated to tolerate a pneumonectomy; lung resection is contraindicated if FEV1 <30% predicted).
Management
Multidisciplinary conversation about the best course of treatment and tumor staging. Resectibility of the tumor (stage I and II disease, specifically IIIa) and operability (if a patient is fit enough to undertake surgery) are important factors to take into account (surgery is not recommended for small-cell cancer). It is essential to have an open dialogue with the patient regarding the risks, advantages, and prognosis. Surgery is only considered in 14% of instances.
Surgery.
Anesthesia: The lung to be operated on is isolated from the ventilatory circuit using a double-lumen endotracheal tube. The lung that will be operated on has a central line inserted ipsilaterally.
The location of the urine catheter and arterial line. To provide effective regional analgesia, a thoracic epidural catheter is frequently inserted. Method: When a bronchial tumor is detected, a rigid bronchoscopy is conducted after anesthesia is administered. Prophylactic antibiotic usage is made. With the patient in a lateral decubitus position, a posterolateral thoracotomy is typically performed with gradual rib distraction. The lung is moved, the tumor's location is determined, and the lymph nodes are examined. The pulmonary artery, vein, and bronchial tree branches are located, and if necessary, a lobectomy is carried out (60 percent of resections). Both the upper and lower lobes of the right lung can be preserved during a bilobectomy. Pneumonectomy, which entails partial resection and rebuilding of the bronchi, is avoided with sleeve resection. Pneumonectomy: one lung is removed in 25 percent of resections.
Air is drained via the front apical drain, while blood or fluid is drained via the posterior basal drain.
Unoperable: Multimodality treatment that combines chemotherapy and radiation therapy increases survival.
Docetaxel is frequently utilized. Erlotinib, an inhibitor of the epidermal growth factor receptor (EGFR), is a biological therapy used as a second-line chemotherapy drug.
Palliative and end-of-life care: includes endobronchial stents, laser treatment for bronchial tumors, problem management, and pain relief.
Complications
Metastases (usually liver, bone, and brain), pleural effusion, pulmonary hemorrhage, lobar or lung collapse, local invasion (e.g., brachial plexus, sympathetic chain, recurrent laryngeal nerve, SVC), and paraneoplastic syndromes (especially common in small-cell carcinomas, e.g., SIADH or ectopic ACTH production; squamous cell carcinomas are associated with hypercalcaemia of malignancy).
Surgery: lesion not surgically resectable (should be less than 5%).
Lobectomy: Reoperations are occasionally necessary due to frequent air leakage.
Pneumonectomy carries a high risk of cardiac arrhythmias, failure or MI, pneumonia and atelectasis, pulmonary oedema, bronchopleural fistula, hemorrhage, and pulmonary embolus. It also carries a significant physiological strain.
Prognosis
Depending on the situation, but not very good. When small-cell carcinoma first manifests, it frequently has spread. 5-year survival rate overall is less than 5%. 25% of patients survive five years after resection for early-stage illness. Pneumonectomy mortality is 8%, but lobectomy mortality is less than 2%.
Introduction
lung primary malignant tumor. The WHO classifies bronchocarcinoma as: Adenocarcinoma, large-cell carcinoma, squamous cell carcinoma, and adenosquamous carcinoma are classified as small cell (20%) and non-small cell (80%).
Etiology
Lung tumors in their primary form: It is believed that factors including asbestos exposure and smoking, whether active or passive, eventually produce in genetic alterations that promote neoplastic transformation.
Tumors typically originate in the main or lobar bronchi (refer to Fig. 2), whereas adenocarcinomas typically manifest in distant locations.
supplementary tumors One common location for metastases is the lung.
Risk Factors
Cigarette smoking, air pollution, occupational exposures (polycyclic hydrocarbons, asbestos, nickel, chromium, cadmium, radon).
Epidemiology
The most prevalent deadly cancer in the West (18% of all cancer fatalities globally), accounting for 35,000 annual deaths in the UK, and three times more common in men than in women.
H HISTORY
5% of cases may show no symptoms despite radiological abnormalities.
Primary cause: Chest discomfort, cough, hemoptysis, and recurrent pneumonia.
Owing to local invasion: For instance, palpitations (arrhythmias), hoarseness and a cow cough caused by the left recurrent laryngeal nerve, dysphagia in the oesophagus, and brachial plexus (Pancoast's tumor).
Weight loss, exhaustion, bone pain or fractures, fits—all may be signs of metastatic disease or paraneoplastic events.
History and Examination
It's possible that none exist.
monophonic wheeze that is fixed.
indications of a pleural effusion or lobar collapse.
symptoms of metastases, such as hepatomegaly or supraclavicular lymphadenopathy.
Horner syndrome.
Investigations
Diagnosis options include sputum cytology, CT or ultrasound-guided percutaneous biopsy, lymph node biopsy, bronchoscopy with brushings or biopsy, and CXR.
TNM staging: Using CT or MRI scans of the head, abdomen, and chest, as well as bone and PET scans, is based on tumor size, nodal involvement, and metastatic metastasis. It is possible to employ invasive techniques like video-assisted thoracoscopy or mediastinoscopy.
Blood: FBC, U&Es, Ca2+ ("bone metastases"), AlkPhos, and LFT. Hypercalcemia is a prevalent condition.
Pre-operative care includes an assessment of general anesthesia, V/Q scan, ECG, and echocardiography, as well as pulmonary function testing (FEV1 >80% anticipated to tolerate a pneumonectomy; lung resection is contraindicated if FEV1 <30% predicted).
Management
Multidisciplinary conversation about the best course of treatment and tumor staging. Resectibility of the tumor (stage I and II disease, specifically IIIa) and operability (if a patient is fit enough to undertake surgery) are important factors to take into account (surgery is not recommended for small-cell cancer). It is essential to have an open dialogue with the patient regarding the risks, advantages, and prognosis. Surgery is only considered in 14% of instances.
Surgery.
Anesthesia: The lung to be operated on is isolated from the ventilatory circuit using a double-lumen endotracheal tube. The lung that will be operated on has a central line inserted ipsilaterally.
The location of the urine catheter and arterial line. To provide effective regional analgesia, a thoracic epidural catheter is frequently inserted. Method: When a bronchial tumor is detected, a rigid bronchoscopy is conducted after anesthesia is administered. Prophylactic antibiotic usage is made. With the patient in a lateral decubitus position, a posterolateral thoracotomy is typically performed with gradual rib distraction. The lung is moved, the tumor's location is determined, and the lymph nodes are examined. The pulmonary artery, vein, and bronchial tree branches are located, and if necessary, a lobectomy is carried out (60 percent of resections). Both the upper and lower lobes of the right lung can be preserved during a bilobectomy. Pneumonectomy, which entails partial resection and rebuilding of the bronchi, is avoided with sleeve resection. Pneumonectomy: one lung is removed in 25 percent of resections.
Air is drained via the front apical drain, while blood or fluid is drained via the posterior basal drain.
Unoperable: Multimodality treatment that combines chemotherapy and radiation therapy increases survival.
Docetaxel is frequently utilized. Erlotinib, an inhibitor of the epidermal growth factor receptor (EGFR), is a biological therapy used as a second-line chemotherapy drug.
Palliative and end-of-life care: includes endobronchial stents, laser treatment for bronchial tumors, problem management, and pain relief.
Complications
Metastases (usually liver, bone, and brain), pleural effusion, pulmonary hemorrhage, lobar or lung collapse, local invasion (e.g., brachial plexus, sympathetic chain, recurrent laryngeal nerve, SVC), and paraneoplastic syndromes (especially common in small-cell carcinomas, e.g., SIADH or ectopic ACTH production; squamous cell carcinomas are associated with hypercalcaemia of malignancy).
Surgery: lesion not surgically resectable (should be less than 5%).
Lobectomy: Reoperations are occasionally necessary due to frequent air leakage.
Pneumonectomy carries a high risk of cardiac arrhythmias, failure or MI, pneumonia and atelectasis, pulmonary oedema, bronchopleural fistula, hemorrhage, and pulmonary embolus. It also carries a significant physiological strain.
Prognosis
Depending on the situation, but not very good. When small-cell carcinoma first manifests, it frequently has spread. 5-year survival rate overall is less than 5%. 25% of patients survive five years after resection for early-stage illness. Pneumonectomy mortality is 8%, but lobectomy mortality is less than 2%.
0 Comments
